Khona Scientific, EVEXIAS seek bioidentical steroid hormone supply chain

Khona Scientific and EVEXIAS signed a letter of intent to explore using biomanufacturing for bioidentical steroid hormones tied to hormone therapy products. The partnership is aimed at diversifying supply away from overseas sourcing and improving continuity for patients and providers.

Why it matters: - The collaboration targets a fragile steroid hormone supply chain that currently depends heavily on sourcing from India and China. - Khona Scientific and EVEXIAS want to build more redundancy into hormone therapy manufacturing so providers have more options for active pharmaceutical ingredients. - The effort could support continuity of care for patients who rely on personalized hormone therapy regimens.

What happened: - Khona Scientific and EVEXIAS signed a letter of intent to explore next-generation steroid hormone supply chain production. - The companies plan to use Khona Scientific’s BiDS™ technology to produce bioidentical steroid hormones for EVEXIAS formulations after validation. - The announcement was made July 30, 2026, from Boulder, Colorado. - The letter of intent covers multiple steroid hormones, including progesterone, estradiol, estrone and estriol.

The details: - BiDS™ is described as a modular biomanufacturing platform that uses abundant, inexpensive and renewable sugars as feedstocks. - The system organizes enzymes from multiple pathways inside a host cell to improve yield, quality, throughput and efficiency. - Khona Scientific says the platform is designed to enable scalable, low-cost, on-demand API production without dependence on specialized inputs. - Estradiol is used for menopause symptoms such as hot flashes and night sweats and for osteoporosis prevention. - Progesterone is often paired with estradiol in menopause treatment and for endometrial protection. - Estradiol and progesterone are also used in infertility treatment, polycystic ovarian syndrome management and assisted reproductive technologies. - EVEXIAS focuses on hormone optimization, functional medicine and proactive longevity care. - EVEXIAS uses the proprietary EvexiPEL® Method, advanced diagnostics and clinical education for providers. - Khona Scientific focuses on synthetic biology and modular biomanufacturing for complex natural product compounds.

Between the lines: - The LOI is a first step, not a finalized manufacturing deal, so validation work still stands between the companies and any commercial rollout. - The partnership reflects a broader push to reduce exposure to agricultural and geopolitical supply constraints in pharmaceutical inputs. - Khona Scientific is positioning BiDS™ as a way to expand beyond current KSM and generic API work into a higher-value therapeutic category.

What’s next: - The companies will validate whether Khona Scientific’s process can be integrated into EVEXIAS hormone therapy formulations. - If the collaboration advances, the partners could move toward a more resilient sourcing model for steroid hormone APIs. - More information is available in EVEXIAS’ announcement and Khona Scientific’s company overview.

The bottom line: - Khona Scientific and EVEXIAS are testing whether biomanufacturing can make steroid hormone supply chains more local, flexible and reliable.